Report Sections

See All Reports

  • HP:0001824: Weight loss
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001824: Weight loss

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (23)


    Name (Synonyms) Correlation
    drug1346 Discussion Board for Social Support+Personalized Feedback Wiki 0.33
    drug4651 Video Chat + Basic Feedback Wiki 0.33
    drug4720 WW Wiki 0.33
    Name (Synonyms) Correlation
    drug1345 Discussion Board for Social Support +Basic Feedback Wiki 0.33
    drug5097 nonfood-specific go/no-go computerized training Wiki 0.33
    drug3092 Partner-assisted intervention Wiki 0.33
    drug2980 Optifast VLCD Program Wiki 0.33
    drug2990 Oral load of oxalate and sucralose Wiki 0.33
    drug3110 Patient-only intervention Wiki 0.33
    drug2095 In Person Behaviour Modification Program Wiki 0.33
    drug2540 Med-South Weight Loss Intervention Wiki 0.33
    drug2469 MOVE!+gshCBT Wiki 0.33
    drug3642 Remote Behaviour Modification Program Wiki 0.33
    drug2468 MOVE! Wiki 0.33
    drug4743 Weight Loss Wiki 0.33
    drug4652 Video Chat +Personalized Feedback Wiki 0.33
    drug4955 food-specific go/no-go computerized training Wiki 0.33
    drug2686 Multi Modal Balance Training Wiki 0.33
    drug2981 Optifast VLCD Transition Phase Wiki 0.33
    drug4750 Whole Health Program Wiki 0.33
    drug2399 Low Oxalate Diet Wiki 0.24
    drug906 Cannabidiol Wiki 0.24
    drug3049 PLACEBO Wiki 0.19

    Correlated MeSH Terms (7)


    Name (Synonyms) Correlation
    D015431 Weight Loss NIH 1.00
    D053040 Nephrolithiasis NIH 0.24
    D056912 Binge-Eating Disorder NIH 0.24
    Name (Synonyms) Correlation
    D050177 Overweight NIH 0.20
    D002032 Bulimia NIH 0.19
    D007669 Kidney Calculi NIH 0.19
    D001068 Feeding and Eating Disorders NIH 0.10

    Correlated HPO Terms (2)


    Name (Synonyms) Correlation
    HP:0000787 Nephrolithiasis HPO 0.24
    HP:0100739 Bulimia HPO 0.19

    Clinical Trials

    Navigate: Correlations   HPO

    There are 9 clinical trials


    1 Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility

    Obesity is a major risk factor for mobility problems in older adults and many older adults use a walking aid to help with their mobility. The use of a walking aid changes normal walking patterns and makes walking harder, leading people to have more functional problems. The purpose of this study is to test the effects of 12 months of a multi-modal balance intervention (MMBI) with supervised weight loss compared to MMBI only on fitness, functional performance, balance, and economy of gait. Participants will be one of 120 participants in the VAMHCS. Participation in this study is voluntary. The research will be conducted at the VAMHCS. The entire study will take approximately 4 years to complete. Subjects' participation in the study will last 24 months.

    NCT02806336
    Conditions
    1. Obesity
    2. Dysmobility
    Interventions
    1. Behavioral: Multi Modal Balance Training
    2. Behavioral: Weight Loss
    MeSH:Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: Distance walked during the 6 minute walking test

    Measure: Change in 6 minute walk distance

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Secondary Outcomes

    Description: VO2peak measured during graded exercise treadmill test to volitional fatigue

    Measure: Change in VO2peak

    Time: baseline, 6 months, 12 months, 24 months

    Description: 6 minute walk with submaximal assessment of oxygen uptake.

    Measure: Change in 6 minute walk with VO2 measurement

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: DXA scan

    Measure: Change in Muscle mass/body composition as assessed by DXA scan

    Time: baseline, 6 months, 12 months, 24 months

    Description: LLDFI Questionnaires

    Measure: Change in Quality of Life, LLDFI

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: Gait biomechanics as assessed by walking mechanics on the GAITmat

    Measure: Change in gait biomechanics

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: Component scores of the standing balance battery, usual gait speed, and repeated chair stands (which make up the short physical performance battery test); as well as overall short physical performance battery score

    Measure: Change in short physical performance battery

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: Dynamic test of balance involving change in stepping direction.

    Measure: Change in four square step test

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: Time to get up from a chair and walk around a cone 8 feet away and sit back down, representing agility.

    Measure: Change in 8 foot up and go

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: CT scan

    Measure: Change in Muscle mass/body composition as assessed by CT scan

    Time: baseline, 6 months, 12 months, 24 months

    Description: Self-reported ability to complete activities of daily living and independent activities of daily living.

    Measure: Change in ADL/IADL questionnaire

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: Self-reported physical activities questionnaire.

    Measure: Change in CHAMPS questionnaire

    Time: baseline, 3 months, 6 months, 12 months, 24 months

    Description: Questionnaire assessing global cognitive function

    Measure: Change in MoCA

    Time: baseline, 3 months, 6 months, 12 months, 24 months
    2 Weight Loss Treatment and CBT for Veterans With Binge Eating

    Inclusion Criteria: aged 21 and older, BMI>=25, and presence of recurrent binge eating on the MOVE! Survey. Exclusion Criteria: more than 4 MOVE! sessions in the prior year; active psychosis or suicidal ideation; medical or psychiatric illness, or cognitive deficits that interfere with providing consent or completing assessments, and; pregnancy or lactation. Participants will be recruited from the VA's MOVE! Program at VA Connecticut Healthcare System (both Newington and West Haven campuses). Those participants who meet eligibility and are interested in the study will meet with a research associate who will obtain written consent. A baseline appointment will be made where the participant will complete written assessments, anthropometric measures (weight, height, blood pressure etc.), along with a blood draw. Participants will then be randomized, by luck of a draw, to either MOVE! or MOVE!+gshCBT treatment. For those randomized to the MOVE! condition, participants will continue in the MOVE! program by meeting with the multidisciplinary team in a group setting once a week for 60 minutes, for 16 weeks. The group sessions are lead by a dietician, health psychologist, and physical therapist. For those randomized to the MOVE!+gshCBT treatments, participants will continue in the MOVE! program as described above, but will also partake in up to 10 individualized sessions over a 3-month period. Participants will be given a treatment manual to read at home, ask to complete daily food logs and work with the study therapist to create goals and complete homework that is geared at examining and changing how participant think about binge eating and how that thinking affects behavior. Lastly, a walking program will also be incorporated into the treatment. For both treatment arms, 3 months from treatment starting, then again at 9 months and 15 months, participants will be asked to complete post and follow up assessments, much like the baseline.

    NCT03234881
    Conditions
    1. Binge Eating Disorder
    Interventions
    1. Behavioral: MOVE!
    2. Behavioral: MOVE!+gshCBT
    MeSH:Weight Loss Bulimia Feeding and Eating Disorders Binge-Eating Disorder
    HPO:Bulimia Decreased body weight Weight loss

    Primary Outcomes

    Description: The EDE-Q is the self-report version of the more intensive EDE interview. Research has documented that the EDE-Q performs well as a measure of change in treatment trials61and has adequate convergence with the interview format62,63. The EDE-Q generates the same frequency data for eating behaviors (binge eating and overeating) in the past 28 days, and the same four subscales reflecting eating disorder pathology.

    Measure: Change in Eating Disorder Examination-Self-report Questionnaire (EDE-Q)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: The EDE is a clinician administered interview that is considered to be the gold standard for diagnosing eating disorders and assessing binge frequency.

    Measure: Change in Binge Episodes from Eating Disorder Examination Interview

    Time: Pre Treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Secondary Outcomes

    Description: The PHQ-9 is a 9-item version, is a self-report measure for the symptoms of depression.

    Measure: Change in Patient Health Questionnaire-9 (PHQ-9)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of Post Traumatic Stress Disorder (PTSD)

    Measure: Change in PTSD Checklist (PCL-5)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: The EuroQol-5D is a 5-item self-report instrument for measurement of quality of life outcomes that has specifically been used in weight loss trials with Veterans.

    Measure: Change in European Quality of Life (EuroQoL-5D)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Other Outcomes

    Description: MOVE! group session attendance will be determined by the number of MOVE! group sessions attended throughout the treatment and follow-up phases.

    Measure: Total number sessions of MOVE! group session attendance

    Time: 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: BMI will be calculated based upon weight in kilograms over height squared in centimeters. Weight will be measured by trained personnel using procedures based on the NHANES Anthropometry Procedures Manual70. Weight will be obtained using a high capacity digital platform scale that is regularly calibrated. Data will be obtained without shoes or coats. Height will be measured in duplicate using a wall-mounted stadiometer at baseline only. Weight data will additionally be collected weekly during treatment.

    Measure: Change in BMI

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: The WCSS is a self-report instrument that assesses the use of specific weight loss behaviors. The measure has been shown to be valid, reliable and predictive of weight loss

    Measure: Change in Weight Control Strategies Scale (WCSS)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: FFQ is a brief dietary screening tool that measures intake of foods related to weight gain and loss.

    Measure: Change in 24 Hour Food Frequency Questionnaire (24 Hour-FFQ)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: The Godin is a 4-item, reliable self-report measure of physical activity that assesses the frequencies of strenuous, moderate and mild exercise and has been validated against accelerometers.

    Measure: Change in Godin Leisure Time Exercise Questionnaire (Godin)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The test is used to detect changes following interventions to improve physical activity, and has been used with a wide range of populations including healthy and patient samples of children, adults and seniors. Overall, good reliability and validity have been reported for this measure although there is some variability depending upon patient sample used76. Among Veterans the measure has demonstrated good discriminant validity, and has detected changes following weight loss intervention.

    Measure: Change in Six-Minute Walk Test (6MWT)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: Treatment satisfaction will be measured with both open-ended questions (e.g., "What aspects of the intervention do you find most helpful? What aspects of the intervention do you find least helpful? What suggestions do you have to improve the program?") and closed-ended questions (e.g., "On a scale of 0 to 10, how would you rate your overall satisfaction with the intervention you received?" Responses range from 0=Completely Dissatisfied to 10=Completely Satisfied).

    Measure: Treatment satisfaction

    Time: 3 months post treatment

    Description: Blood samples will be collected, after overnight fasting (12 hours), and analyzed for HbA1c.

    Measure: Change in HbA1c

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: Blood samples will be collected, after overnight fasting (12 hours), and analyzed for Lipid Profile Analysis (total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglycerides). Total cholesterol, HDL, LDL and triglycerides are measured by cholesterol levels in milligrams (mg) of cholesterol per deciliter (dL).

    Measure: Change in Lipid Profile Analysis (Cholesterol)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: Systolic and diastolic will be measured with a digital wrist blood pressure monitor and the average of three measurements, at each assessment point, will be used.

    Measure: Change in Blood Pressure (BP)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: Waist Circumference will be measured in inches, and will be assessed with a measuring tape placed horizontally just above the iliac crest, after completion of a respiratory cycle.

    Measure: Change in Waist Circumference

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: Status determined by a diabetes diagnosis in the electronic health record.

    Measure: Diabetes Status (covariate)

    Time: Pre treatment

    Description: Heart rate will be taken with a digital wrist blood pressure monitor and the average of three measurements, at each assessment point. Heart rate is measured in beats per minute.

    Measure: Change in Heart Rate (HR)

    Time: Pre treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: Use determined by statin prescription in the electronic health record. Scores are dichotomous (Yes/No) with YES being worse.

    Measure: Statin Use (covariate)

    Time: Pre treatment

    Description: A self-administered scale used to assess features of loss of control over eating.

    Measure: Loss of Control Overeating Scale (LOCES)

    Time: Pre Treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment

    Description: A self-administered scale used to assess the features of food addiction. Scores range from 0-28 with higher scores reflecting worse outcome.

    Measure: Modified Yale Food Addiction Scale 2.0 (mYFAS 2.0)

    Time: Pre Treatment, 3 month post treatment, 9 month post treatment, 15 month post treatment
    3 Using Partners to Enhance Long-Term Weight Loss

    This study involves an evaluation of the role of domestic partner support in a comprehensive weight loss initiation and maintenance program.

    NCT03801174
    Conditions
    1. Obesity
    Interventions
    1. Behavioral: Partner-assisted intervention
    2. Behavioral: Patient-only intervention
    MeSH:Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: Measured on a calibrated, digital scale to the nearest 0.1 kg, assessed every 6 months with 24 months as primary endpoint

    Measure: Body weight (kg)

    Time: 24 months

    Secondary Outcomes

    Description: average estimated daily intake from ASA24 Dietary Assessment Tool, assessed every 6 months with 24 months as primary endpoint

    Measure: Caloric intake (kcal)

    Time: 24 months

    Description: average daily minutes of moderate activity over past 7 days from Fitbit, assessed every 6 months with 24 months as primary endpoint

    Measure: Physical activity

    Time: 24 months

    Other Outcomes

    Description: Score based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)

    Measure: Transformation of motivation for diet

    Time: 3 months

    Description: 5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)

    Measure: Outcome efficacy for diet

    Time: 3 months

    Description: 5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)

    Measure: Couple efficacy for diet

    Time: 3 months

    Description: 9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)

    Measure: Social support for diet

    Time: 3 months

    Description: 5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)

    Measure: Use of communal coping strategies for diet

    Time: 3 months

    Description: Score based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)

    Measure: Transformation of motivation for physical activity

    Time: 3 months

    Description: 5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)

    Measure: Outcome efficacy for physical activity

    Time: 3 months

    Description: 5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)

    Measure: Couple efficacy for physical activity

    Time: 3 months

    Description: 9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)

    Measure: Social support for physical activity

    Time: 3 months

    Description: 5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)

    Measure: Use of communal coping strategies for physical activity

    Time: 3 months
    4 Randomized Explanatory Trial of a Mediterranean Dietary Pattern Weight Loss Intervention for Primary Care Practices

    This study will compare a new weight loss program that focuses on a healthy eating pattern, with WW™ (formally Weight Watchers), an effective and widely available weight loss program. Study researchers have developed an adapted version of the Mediterranean eating pattern to be more acceptable and realistic for southerners; this adapted version is known as "Med-South." Those who take part in the study will be randomly assigned to either the Med-South weight loss program or WW™. Both programs will last for 2 years with measurement visits at the start of the study and at 4-, 12- and 24-month follow-up. While the primary outcome measured by the trial will be weight loss at 24 months, researchers will collect other data which may show additional health benefits of the Med-South diet. The study team will measure blood markers of inflammation, which are known to improve with better diet quality. Researchers will also measure participants' skin carotenoid levels, which increase with greater fruit and vegetable consumption. The study will be conducted within 2 regional catchment areas (n=360 participants) representing a diverse spectrum of patients and settings. Patients with a BMI ≥ 30 kg/m^2 will be enrolled and randomized to intervention or augmented usual care. To assure adequate subgroup representation, ≥ 40% of the sample will have diabetes, ≥ 40% will be male, and ≥ 40% will be African American. The intervention will be delivered in 3 phases over 24 months by research staff: Phase I (4 months) focuses on adopting a Med-style dietary pattern; Phase II (8 months) on weight loss; and Phase III (12 months) on weight loss maintenance. Outcomes will be assessed at 4, 12, and 24 months. The primary outcome is weight loss at 24 months. Secondary outcomes include change in physiologic, behavioral, and psychosocial measures. Researchers will also assess implementation cost and the incremental cost-effectiveness of the intervention relative to the augmented usual care group.

    NCT04302727
    Conditions
    1. Weight Loss
    2. Diet, Healthy
    3. Card
    4. Cardiovascular Risk Factor
    Interventions
    1. Behavioral: Med-South Weight Loss Intervention
    2. Behavioral: WW
    MeSH:Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds.

    Measure: Mean Weight Change from Baseline to Month 24

    Time: Baseline, Month 24

    Secondary Outcomes

    Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds.

    Measure: Mean Weight Change from Baseline to Months 4 and 12

    Time: Baseline, Months 4 and 12

    Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds. Change in weight will be assessed across 3 pre-specified subgroups: 1) with vs. without diabetes; 2) females vs. males; and 3) whites vs. African Americans.

    Measure: Mean Weight Change from Baseline through Follow-Up by Sub-Groups

    Time: Baseline, Months 4, 12, and 24

    Description: Weight will be collected by study staff who are masked to treatment using scales tested monthly for accuracy up to 350 pounds. Assess difference between study groups in percentage losing ≥ 5% body weight for all participants and across 3 pre-specified subgroups: 1) participants with vs. without diabetes; 2) females vs. males; and 3) Whites vs. African Americans.

    Measure: Percentage Weight from Baseline through Follow-Up

    Time: Baseline, Months 4, 12, and 24

    Description: Blood pressure assessed by Omron-907xl, average of 3 readings.

    Measure: Mean Change in Systolic Blood Pressure from Baseline through Follow-Up

    Time: Baseline, Months 4, 12, and 24

    Description: Blood pressure assessed by Omron-907xl, average of 3 readings.

    Measure: Mean Change in Diastolic Blood Pressure from Baseline through Follow-Up

    Time: Baseline, Months 4, 12, and 24

    Description: Total cholesterol assessed by commercial lab (LabCorp).

    Measure: Mean Change in Total Cholesterol from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: HDL-Cholesterol assessed by commercial lab (LabCorp).

    Measure: Mean Change in HDL-Cholesterol from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Triglycerides as assessed by commercial lab (LabCorp).

    Measure: Mean Change in Triglycerides from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Calculated from above lipid assessments by commercial lab (LabCorp).

    Measure: Mean Change LDL-cholesterol from Baseline through Follow-up

    Time: Baseline, Month 4, 12, and 24

    Description: A1c assessed by commercial lab (LabCorp).

    Measure: Mean Change in A1c from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: CRP assessed by commercial lab (LabCorp).

    Measure: Mean Change in CRP from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Assessed by independent lab blinded to participant arm.

    Measure: Mean Change in IL-6 from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Assessed by independent lab blinded to participant arm.

    Measure: Mean Change in TNF-alpha from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Evaluated as the sum of 3 measures assessed by veggie-meter by Longevity Link Corporation.

    Measure: Mean Change in Skin Carotenoids from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: The Euro Quality of Life five Dimensions Questionnaire EQ-5D-5L scale measures patients' quality of healthy living. It has 5 items (Mobility, Self-care, Usual activities, Pain/discomfort, Depression/anxiety). Each item contains 5 levels: 1= no difficulty, 2= slight difficulty, 3= moderate difficulty, 4= serious difficulty, 5= extremely serious difficulty. The higher the score has the worse the health. Then, the score calculation of the European Five-Dimensional Health Scale is based on the calculation formula published by the EuroQol Group. Based on 5 combinations of different severity levels, a score of 0 to 1 is obtained. 0 is the least healthy and 1 is the most healthy.

    Measure: Mean Change in Quality of Life Scale from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: The AHEI-2010 is calculated from items on the Willett Food Frequency Questionnaire. It addresses intake of foods and nutrients consistently associated with lower risk for chronic diseases in the literature. The AHEI-2010 score is comprised of 11 sub-scales, each scored from 0 to 10, yielding a total score with a range of 0-110. A higher score indicates a more healthful dietary pattern.

    Measure: Mean Change in Alternate Healthy Eating Index (AHEI)-2010 from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: The GPAQ was developed by the WHO for physical activity surveillance. It collects information on physical activity participation in three settings (or domains) as well as sedentary behavior. The domains are: activity at work, travel to and from places, and recreational activities. The summary measure will be the sum of all activity per day with a higher score indication more physical activity.

    Measure: Mean Change in Global Physical Activity Questionnaire (GPAQ) from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: The Weight Efficacy Lifestyle Questionnaire Short-Form (WEL-SF1) is a short version of the original Weight-Efficacy Lifestyle Questionnaire and includes 8 questions and 1 situational component representing "confidence in ability to resist eating." Three of the questions are related to emotional eating situations, two to availability, one to social pressure, one to positive activities, and one to physical discomfort. Scoring: The instrument range scores on a Likert-scale from 0 (not at all confident) to 10 (very confident), with sum scores between 0 and 80. High scores are associated with high eating self-efficacy.

    Measure: Mean Change in Weight Loss Self-Efficacy from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Treatment Self-regulation Questionnaire (TSRQ) measures the quality of motivation for a particular health goal. Motivation is psychological energy directed at a particular goal such as weight loss. This measure assesses three types of motivation: autonomous self-regulation, controlled self-regulation, and a-motivation or lack of motivation. This 15-item scale will focus on the reasons why people would either start eating a healthier diet or continue to do so. Scoring: Participants rate each statement on a 7-point Likert scale ranging from 1 (not at all true) to 7 (very true). It assesses the degree to which a person's motivation for eating a healthy diet is autonomous or self-determined. The three sub-scale scores can be used separately or a Relative Autonomous Motivation score can be calculated. A higher score indicates greater motivation.

    Measure: Mean Change in Dietary Self-Regulation from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: The Three Factor Eating Questionnaire (18 item revised version) measures eating attitudes with scales representing three dimensions of eating behavior: cognitive restraint (control over food intake in order to influence body weight / body shape), uncontrolled eating (loss of control over eating), and emotional eating (eating in response to positive and negative emotions). Scoring: Each scale (dimension) is scored separately. Six of the eighteen items measure cognitive restraint, nine measure uncontrolled eating, and three measure emotional eating. Higher scores indicate greater cognitive restraint.

    Measure: Mean Change in Eating Attitudes from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Perceived self-efficacy is regarded as a suitable predictor of behavioral intentions and reported health behaviors. This 5-item scale of perceived self-efficacy measuring action self-efficacy and coping self-efficacy related to healthful eating behaviors. Responses are on a 4-point scale of 'very uncertain' to 'very certain.' Scoring: Higher scores indicate higher perceived self-efficacy. Validation: Evidence for the validity of the scales has been published in several articles. Cronbach's alpha for the nutrition self-efficacy measure ranges from 0.79 to 0.85.

    Measure: Mean Change in Diet Self-Efficacy from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: EARLY Self-Weighing Questionnaire: This is a 2-item screener measures frequency of self-weighing and access to a bathroom scale. It was adapted from the Pound of Prevention Health Habits Questionnaire, Year 2. Validity of construct confirmed in Linde et al, 2005, as reports of higher weighing frequency was associated with greater 24-month weight loss or less weight gain. Scoring: Higher scores indicate higher frequency of self-weighing and access to a bathroom scale.

    Measure: Mean Change in Self-Weighing Behaviors from Baseline through Follow-Up

    Time: Baseline, Month 4, 12, and 24

    Description: Computed as the incremental cost per kilogram of weight loss relative to control. The budgetary assessment will quantify the total and per participant costs of intervention delivery from the health system perspective using an Activity Based Costing (ABC) approach and cost tracking forms that the health economist (Finkelstein) has developed and refined in past behavioral trials. Using this approach, all relevant labor, materials and supplies, contracted services, and other relevant costs required to deliver the interventions will be captured by key activities

    Measure: Economic Outcome--Incremental Cost-Effectiveness

    Time: Month 24

    Description: The numerator for this analysis will be the incremental program delivery costs of the intervention relative to control, minus any cost offsets based on differences in health services and medication use across arms. The denominator will be the incremental QALYs based on average differences in Euro Quality of Life five Dimensions Questionnaire (EQ-5D-5L) scores across arms collected at each assessment point. These scores can be used to quantify net QALY differences during the intervention period. EQ-5D-5L scale measures patients' quality of healthy living. It has 5 items (Mobility, Self-care, Usual activities, Pain/discomfort, Depression/anxiety). The score calculation of the European Five-Dimensional Health Scale is based on the calculation formula published by the EuroQol Group. Based on 5 combinations of different severity levels, a score of 0 to 1 is obtained. 0 is the least healthy and 1 is the most healthy.

    Measure: Economic Outcome--Incremental Cost per Quality Adjusted Life Year (QALY) gained

    Time: Month 24
    5 Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic

    The current pilot study will explore the optimal cost-effective treatment configuration for online group-based weight control by focusing on two aspects of our existing treatment program which have significant associated cost and determine which contribute meaningfully to weight loss outcomes. Specifically, we will explore whether adding synchronous group social support (weekly group video chat sessions facilitated by a trained weight loss counselor) to on demand (asynchronous) social support provided through the program discussion board significantly increases weight losses achieved. We will also examine whether detailed feedback on dietary and physical activity self-monitoring records from a counselor enhances weight loss outcomes in comparison with basic feedback. Finally, we will examine the cost efficiency of the treatment constellations. Further, this pilot study will also explore the feasibility of recruiting participants nationally (rather than just locally) and the capture of data electronically (including body weight measurements) without any in-person contact.

    NCT04514900
    Conditions
    1. Obesity
    Interventions
    1. Behavioral: Video Chat +Personalized Feedback
    2. Behavioral: Video Chat + Basic Feedback
    3. Behavioral: Discussion Board for Social Support +Basic Feedback
    4. Behavioral: Discussion Board for Social Support+Personalized Feedback
    MeSH:Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: Change in body weight from baseline calculated as kg lost

    Measure: Weight loss

    Time: Baseline, 2 and 4 months

    Description: 1 - [follow-up body weight/ baseline body weight] = % body weight change

    Measure: Change in body weight from baseline calculated as % of body weight lost

    Time: 2 and 4 months

    Secondary Outcomes

    Description: Self-monitoring rates for daily weighing and will be calculated as the total number of days of weight submitted over the 4 month period divided by the total number of days of potential self-weighing.

    Measure: Treatment Engagement: daily weighing

    Time: Weeks 1 to 16

    Description: Self-monitoring rates for daily dietary self monitoring will be calculated as the total number of weeks of digital food diaries submitted over the 4 month period divided by the total number of weeks of potential digital diary submissions.

    Measure: Treatment Engagement: weekly food journal submissions

    Time: Weeks 1 to 16

    Description: Percent of weekly module completion will be calculated as the total number of weeks of completed modules submitted over the 4 month period divided by 16 (the total number of modules available).

    Measure: Treatment Engagement: completion of the 16 weekly interactive online modules

    Time: Weeks 1 to 16

    Description: Percent of weekly video chat attendance will be calculated as the total number of weeks each participant attended video chat over the 4 month period divided by 16 (the total number of video chats available).- Collected only for those randomized to a condition with video chat

    Measure: Treatment Engagement: Attendance at Video Chat condition

    Time: Weeks 1 to 16

    Other Outcomes

    Description: All participants will be administered the Supportive Accountability Questionnaire to determine whether there is a difference in accountability experienced by participants depending on which intervention they receive.

    Measure: Supportive Accountability

    Time: 2 months and 4 months

    Description: All participants will be administered the Perceived Social Support Scale to determine whether perceptions of social support differ depending on which intervention participants receive.

    Measure: Social Support

    Time: baseline, 2 months and 4 months

    Description: Actual counselor time spent in delivering group video chats and giving feedback will be tracked in order to quantify the relative costs of delivering behavioral weight control programs.

    Measure: Cost-Effectiveness Analyses

    Time: Weeks 1 to 16

    Description: All participants will be queried as to their expectations and preferences in treatment prior to intervention.using a measure designed for the current study

    Measure: Treatment Expectations

    Time: Baseline

    Description: Each month participants will be asked to complete a survey inquiring about the helpfulness of the treatment modules, skills building assignments, and satisfaction with their treatment experiences in the previous month. Response options will be a 5-point Likert scale with 1=not at all helpful/useful and 5=extremely helpful/useful on a measure that is developed for this study and tailored to the treatment elements provided.

    Measure: Treatment Satisfaction

    Time: through study completion, up to 24 weeks

    Description: Participants self report on their self management behaviors

    Measure: Self Regulation Questionnaire

    Time: baseline
    6 The Effect of Go/No-Go Training Dosage on Weight Loss, Food Evaluation, and Disinhibition in Overweight and Obese Individuals: A Randomized Controlled Trial

    The purpose of this study is to assess the effect of a food-specific Go/No-Go (GNG) computerized training task on weight loss, food evaluation, and disinhibition in a population of overweight and obese individuals.

    NCT04624087
    Conditions
    1. Overweight and Obesity
    Interventions
    1. Behavioral: food-specific go/no-go computerized training
    2. Behavioral: nonfood-specific go/no-go computerized training
    MeSH:Overweight Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: Body weight will be measured by participant using personal or university scale. Participants will take a picture of their weight send it to the research team (Due to COVID-19 precautions, in person weighing is not possible).

    Measure: Change in body weight from baseline to post 4-week intervention, to 6-month follow-up

    Time: baseline, post 4-week intervention, 6-month follow-up

    Description: This will be measured using the Disinhibition subscale of the Three Factor Eating Questionnaire; minimum value = 0; maximum value = 16; higher scores for this measure means worse outcomes

    Measure: Change in disinhibition scores from baseline to post 4-week intervention, to 6-month follow-up.

    Time: baseline, post 4-week intervention, 6-month follow-up

    Description: This will be measured using a food frequency questionnaire assessing food intake over the previous month.

    Measure: Change in frequency of food consumption from baseline to post 4-week intervention, to 6-month follow-up.

    Time: baseline, post 4-week intervention, 6-month follow-up

    Secondary Outcomes

    Description: This will be measured using the binge eating questions of the Eating Disorder Examination Questionnaire; minimum value = 0; maximum value = unlimited; higher scores for this measure means worse outcomes

    Measure: Change in binge eating behaviors from baseline to post 4-week intervention, to 6-month follow-up.

    Time: baseline, post 4-week intervention, 6-month follow-up

    Description: This will be measured using a visual analog scale; minimum value = -100; maximum value = 100; higher scores for this measure on healthy foods means better outcomes, higher scores on this measure for unhealthy foods means worse outcomes

    Measure: Change in liking of foods from baseline to post 4-week intervention, to 6-month

    Time: baseline, post 4-week intervention, 6-month follow-up

    Description: This will be measured using an impulsive food choice test.

    Measure: Change in automatic responses to healthy and unhealthy foods from baseline to post 4-week intervention, to 6-month

    Time: baseline, post 4-week intervention, 6-month follow-up
    7 Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone

    This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in obese calcium oxalate stone formers.

    NCT04633811
    Conditions
    1. Kidney Stone
    Interventions
    1. Dietary Supplement: Low Oxalate Diet
    2. Dietary Supplement: Oral load of oxalate and sucralose
    3. Dietary Supplement: Optifast VLCD Program
    4. Dietary Supplement: Optifast VLCD Transition Phase
    MeSH:Kidney Calculi Nephrolithiasis Weight Loss
    HPO:Decreased body weight Nephrolithiasis Weight loss

    Primary Outcomes

    Description: Subjects will ingest a controlled diet low in oxalate and collect 2 x 24-hour urines before and after the Optifast VLCD Program. The utilization of a low oxalate diet allows assessment of the change in contribution of endogenous oxalate synthesis to the urinary oxalate pool.

    Measure: Measurement of 24 hour urinary oxalate excretion

    Time: Day 4
    8 A Mixed Retrospective-prospective, Observational Study Evaluating the Efficacy of Counselling in a Remote Setting Compared to an In-person Setting on Weight Loss, in Obese Patients With Body Mass Index > 35 Kg/m2 and Enrolled in the Behaviour Modification Program at the Bariatric Centre of Excellence at St Joseph's Healthcare Hamilton.

    The COVID-19 pandemic has created fear, financial difficulties and interruptions in the lives of patients and healthcare providers. As a result, many patients suffering from chronic conditions such as obesity have had their treatment disrupted by the pandemic. The Bariatric Medical Weight Management Clinic at St. Joseph's Healthcare Hamilton transitioned its weight loss and maintenance counselling classes to a remote (online) platform in response to the pandemic. The remote weight loss and maintenance classes allows patients to continue receiving treatment for obesity from their homes. The remote weight loss and maintenance program is conducted on a safe platform that has been thoroughly reviewed and approved by St. Joseph's Privacy Committees. The aim of this study is to learn whether the remote weight loss and maintenance classes can lead to similar weight loss compared to the in-person weight loss and maintenance classes that were offered to patients before the COVID-19 pandemic. This study also aims to gather feedback about the program to improve its delivery and patients' experiences.

    NCT04658550
    Conditions
    1. Obesity
    Interventions
    1. Other: Remote Behaviour Modification Program
    2. Other: In Person Behaviour Modification Program
    MeSH:Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: To evaluate the efficacy of counselling in a remote setting compared to an in-person setting in achieving weight loss among adult patients with obesity enrolled in the behaviour modification program

    Measure: Mean Percentage Change in Body Weight

    Time: Baseline to Week 26

    Secondary Outcomes

    Description: Patient satisfaction and barriers to participation associated with the remote weight loss and maintenance program as assessed by the Bariatric Centre of Excellence Virtual Medical Program Satisfaction Survey.

    Measure: Patient satisfaction and barriers to participation

    Time: Week 26

    Description: Change in blood pressure

    Measure: Change in blood pressure

    Time: Baseline to Week 26

    Description: Change in lipid profile including total cholesterol, triglycerides, low density lipoprotein and high density lipoprotein

    Measure: Change in lipid profile

    Time: Baseline to Week 26

    Description: Change in fasting blood glucose

    Measure: Change in fasting blood glucose

    Time: Baseline to Week 26

    Description: Change in heart rate

    Measure: Change in heart rate

    Time: Baseline to Week 26

    Description: Change in HbA1C

    Measure: Change in HbA1C

    Time: Baseline to Week 26
    9 Koa Family Study--A Community-Based Intervention to Improve Health and Well-Being

    Wholehearted living touches every aspect of life, from eating nourishing foods, to enjoying enough physical activity, to cultivating relationships that support healthy choices, to joining with neighbors to stand up for positive changes, and more. Unfortunately, for many low-income Californians, the idea of wholehearted living is an aspiration and not a reality. Koa Family: Strong, Healthy, Whole is an approach designed to make wholehearted living available for all. The Approach Koa Family is a 4-month journey to establish "micro-communities" of women supporting one another- mind, body, and spirit. The foundation of this approach is a new, custom-designed, online Whole Health Program (WHP) that addresses healthy eating, physical activity, and weight management within the context of wholehearted living. Low-income women and a lifestyle coach will meet weekly in a virtual platform to learn, experience, grow, and thrive as they reach their diet, physical activity, and weight management goals. Participants in the WHP will receive additional encouragement and access to local resources through a private and secure Facebook group. The group will provide a place for women to continue their wholehearted health journeys beyond the weekly meetings. Koa Family participants also will be invited to take part in a neighborhood tree planting campaign to create real, long-lasting, healthy changes to the environment in which they live. The Study Koa Family, with WHP at its core, is the product of extensive formative research both nationally and within low-income California communities. Koa Family will be introduced in Sacramento County in February 2021. It will be evaluated for effectiveness among 120 low-income, Supplemental Nutrition Assistance Program (SNAP)-Ed eligible women using a randomized controlled trial study design, the gold standard for assessing effectiveness of an intervention. Outcomes include changes in Body Mass Index, diet, and physical activity measured at 4 and 6 months from baseline. An economic analysis will assess the cost-effectiveness of Koa Family, while qualitative methods will identify mediating factors related to the study outcomes. Funding Koa Family is a project of the Population Health Group at the University of California, Davis, Center for Healthcare Policy and Research. Funding is provided by the United States Department of Agriculture Supplemental Nutrition Assistance Program-Education and the California Department of Forestry and Fire Protection (CalFIRE).

    NCT04662593
    Conditions
    1. Obesity
    2. Overweight
    3. Diet, Healthy
    4. Social Interaction
    5. Weight Loss
    Interventions
    1. Behavioral: Whole Health Program
    MeSH:Overweight Weight Loss
    HPO:Decreased body weight Weight loss

    Primary Outcomes

    Description: Weight (kg) measured with an electronic scale

    Measure: Change from Baseline Weight at 4 Months

    Time: Difference in weight between baseline and 4 months

    Description: Weight (kg) measured with an electronic scale

    Measure: Change from Baseline Weight at 6 Months

    Time: Difference in weight between baseline and 6 months

    Description: weight (kg)/height (m) x height (m)

    Measure: Change from Baseline Body Mass Index (BMI) at 4 Months

    Time: Difference in BMI between baseline and 4 months

    Description: weight (kg)/height (m) x height (m)

    Measure: Change from Baseline Body Mass Index (BMI) at 6 Months

    Time: Difference in BMI between baseline and 6 months

    Description: Measured with the Dietary Screener Questionnaire (NHANES 2009-10) to examine quality of participants' diet

    Measure: Change from Baseline Diet at 4 Months

    Time: Difference in diet between baseline and 4 months

    Description: Measured with the Dietary Screener Questionnaire (NHANES 2009-10) to examine quality of participants' diet

    Measure: Change from Baseline Diet at 6 Months

    Time: Difference in diet between baseline and 6 months

    Description: Measured using the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance Survey Physical Activity Module

    Measure: Change from Baseline Physical Activity (PA) at 4 Months

    Time: Difference in PA between baseline and 4 months

    Description: Measured using the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance Survey Physical Activity Module

    Measure: Change from Baseline Physical Activity (PA) at 6 Months

    Time: Difference in PA between baseline and 6 months

    Description: Well-being and general health measured with Short Form-36v2; There are 8 sections each scored 0-100 with a high score indicating less disability

    Measure: Change from Baseline Health-Related Well-being at 4 Months

    Time: Difference in health-related well-being between baseline and 4 months

    Description: Well-being and general health measured with Short Form-36v2

    Measure: Change from Baseline Health-Related Well-being at 6 Months

    Time: Difference in health-related well-being between baseline and 6 months

    HPO Nodes


    HP:0001824: Weight loss
    Genes 337
    NABP1 PTPN22 MC2R NOS1 LMNA DNAJC13 GALC IGH HSPG2 RPS20 NPM1 HLCS VPS35 ZBTB16 RHBDF2 CUL4B CDKN2C EWSR1 VHL SLC39A4 SDHD POU6F2 RRM2B SIGMAR1 FANCM SCNN1A IKZF1 PRNP AKT1 TP53 MALT1 KCNJ11 ATM IL6 MPL TCF4 PALB2 GALT IL12B TSHR HLA-DPA1 KRT10 EPCAM JAK2 EDN3 TP53 CFTR IL10 RAD51C NAB2 POLG FANCE GCK REST TGFBR2 KRT1 B2M TGFB1 SDHD GBA IGH SCNN1B CHEK2 H19 ATRIP DCTN1 BCOR SDHB GATA4 SLC9A6 FANCC SNCA TRAIP RARA BRIP1 PIK3R1 MEN1 ERCC3 TXNRD2 CACNA1S RB1 ERCC4 NRTN BRCA1 MPL PTEN CDKN2A PIK3CA PMS1 CDKN2B CCND1 FANCG BRCA2 HLA-DPB1 POLG MLX TRIP13 AVP PMS2 FOXP3 MST1 SLC22A4 CBL DLST COL12A1 BRCA2 TTR MAFB PLA2G6 SRSF2 TRIM28 DNMT3A EDNRB RBBP8 THPO PCNT SDHAF1 CRLF1 KDSR STAT5B SCNN1G SDHB CTLA4 ECE1 EPAS1 TET2 MRAP SPG11 COL6A2 SNCA CDH23 SUCLA2 GBA DAXX MLH1 BCL2 DIS3L2 FOXP1 KRAS IL23R STAT3 SLC6A8 PRKAR1A RRM2B TYMP FANCD2 RNF168 ERCC2 EIF4G1 LRRK2 SMAD4 GNPTAB IGH NDP NBN LPIN2 MAD2L2 NF1 SDHAF2 HLA-DQB1 CENPJ FANCL CALR FANCB WT1 UNC80 FAN1 PRTN3 TET2 VPS13A NOD2 HLA-B SEMA3D PRNP SDHD SLX4 SDHD GJA1 GIGYF2 TLR4 PRNP FLI1 GJB3 ABCC8 TP53 TSHR GATA2 SDHC BRCA2 STAR SEMA4A SDHA IRF2BP2 PALB2 TET2 IFNGR1 BRCA1 ASXL1 PSAP GJB4 CACNA1S KIF1B TRPV4 STAT3 FANCF RET PTEN LMNA ALS2 KCNJ18 UBE2T KRAS JAK2 ACAT1 STAT4 PTEN HLA-DRB1 ACADM C4A EIF2AK3 TMEM127 RUNX1 ZMPSTE24 MAX CCND1 CCR1 MDH2 HTT UBAC2 BTK SLC2A3 MSH6 HFE BIRC3 UNC80 MEFV TP53 BMPR1A PLK4 PALLD FAS MECP2 HLA-DQB1 BCL10 ERCC4 BCL6 NUMA1 PADI4 RAD51 JAK2 SCNN1G MSH2 F5 XRCC2 CNTNAP1 PDX1 FANCI COL6A3 ERAP1 SDHC POLG CDC73 JAK2 HLA-DRB1 PTPN22 KIF1B PML TRIM28 FIP1L1 MLH3 STAT6 RFWD3 HTT HAVCR2 HMGCL TBL1XR1 RET FH KLRC4 PTPN22 ERCC4 HLA-B KCNJ18 BMPR1A HLA-DRB1 SDHB MPL ATRX ATP7B AK2 IL10 FANCA VHL HLA-DRB1 LRP12 TRIM37 GABRA3 IL12A-AS1 SCNN1A GPC3 NNT SCNN1B TYMP CDKN1B DCTN1 ATR GPR35 CIITA HLA-DQA1 NOD2 CDKN1A CENPE FUS WT1 SLC25A11 RET JPH3 SDHB JPH3 IL12A WT1 CD244 LIPA CEP152 SLC11A1 COL6A1 GDNF ERCC5 SEMA3C NFKBIL1 BTNL2 NALCN INS HLA-B CYP24A1 PANK2 SDHA
    Protein Mutations 2
    I148M P12A

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0001824: Weight loss
    Genes 337
    NABP1 PTPN22 MC2R NOS1 LMNA DNAJC13 GALC IGH HSPG2 RPS20 NPM1 HLCS VPS35 ZBTB16 RHBDF2 CUL4B CDKN2C EWSR1 VHL SLC39A4 SDHD POU6F2 RRM2B SIGMAR1 FANCM SCNN1A IKZF1 PRNP AKT1 TP53 MALT1 KCNJ11 ATM IL6 MPL TCF4 PALB2 GALT IL12B TSHR HLA-DPA1 KRT10 EPCAM JAK2 EDN3 TP53 CFTR IL10 RAD51C NAB2 POLG FANCE GCK REST TGFBR2 KRT1 B2M TGFB1 SDHD GBA IGH SCNN1B CHEK2 H19 ATRIP DCTN1 BCOR SDHB GATA4 SLC9A6 FANCC SNCA TRAIP RARA BRIP1 PIK3R1 MEN1 ERCC3 TXNRD2 CACNA1S RB1 ERCC4 NRTN BRCA1 MPL PTEN CDKN2A PIK3CA PMS1 CDKN2B CCND1 FANCG BRCA2 HLA-DPB1 POLG MLX TRIP13 AVP PMS2 FOXP3 MST1 SLC22A4 CBL DLST COL12A1 BRCA2 TTR MAFB PLA2G6 SRSF2 TRIM28 DNMT3A EDNRB RBBP8 THPO PCNT SDHAF1 CRLF1 KDSR STAT5B SCNN1G SDHB CTLA4 ECE1 EPAS1 TET2 MRAP SPG11 COL6A2 SNCA CDH23 SUCLA2 GBA DAXX MLH1 BCL2 DIS3L2 FOXP1 KRAS IL23R STAT3 SLC6A8 PRKAR1A RRM2B TYMP FANCD2 RNF168 ERCC2 EIF4G1 LRRK2 SMAD4 GNPTAB IGH NDP NBN LPIN2 MAD2L2 NF1 SDHAF2 HLA-DQB1 CENPJ FANCL CALR FANCB WT1 UNC80 FAN1 PRTN3 TET2 VPS13A NOD2 HLA-B SEMA3D PRNP SDHD SLX4 SDHD GJA1 GIGYF2 TLR4 PRNP FLI1 GJB3 ABCC8 TP53 TSHR GATA2 SDHC BRCA2 STAR SEMA4A SDHA IRF2BP2 PALB2 TET2 IFNGR1 BRCA1 ASXL1 PSAP GJB4 CACNA1S KIF1B TRPV4 STAT3 FANCF RET PTEN LMNA ALS2 KCNJ18 UBE2T KRAS JAK2 ACAT1 STAT4 PTEN HLA-DRB1 ACADM C4A EIF2AK3 TMEM127 RUNX1 ZMPSTE24 MAX CCND1 CCR1 MDH2 HTT UBAC2 BTK SLC2A3 MSH6 HFE BIRC3 UNC80 MEFV TP53 BMPR1A PLK4 PALLD FAS MECP2 HLA-DQB1 BCL10 ERCC4 BCL6 NUMA1 PADI4 RAD51 JAK2 SCNN1G MSH2 F5 XRCC2 CNTNAP1 PDX1 FANCI COL6A3 ERAP1 SDHC POLG CDC73 JAK2 HLA-DRB1 PTPN22 KIF1B PML TRIM28 FIP1L1 MLH3 STAT6 RFWD3 HTT HAVCR2 HMGCL TBL1XR1 RET FH KLRC4 PTPN22 ERCC4 HLA-B KCNJ18 BMPR1A HLA-DRB1 SDHB MPL ATRX ATP7B AK2 IL10 FANCA VHL HLA-DRB1 LRP12 TRIM37 GABRA3 IL12A-AS1 SCNN1A GPC3 NNT SCNN1B TYMP CDKN1B DCTN1 ATR GPR35 CIITA HLA-DQA1 NOD2 CDKN1A CENPE FUS WT1 SLC25A11 RET JPH3 SDHB JPH3 IL12A WT1 CD244 LIPA CEP152 SLC11A1 COL6A1 GDNF ERCC5 SEMA3C NFKBIL1 BTNL2 NALCN INS HLA-B CYP24A1 PANK2 SDHA
    Protein Mutations 2
    I148M P12A

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook